Alphabet is doubling down on its AI-for-science ambitions, pouring billions into a DeepMind spin-off to challenge the high-margin world of pharmaceutical innovation.
Isomorphic Labs, an AI drug discovery company spun out of Google’s DeepMind, is raising over $2 billion in a new funding round, signaling parent company Alphabet's strategy to dominate the entire AI stack from enterprise software to fundamental science.
"Alphabet holds a significant spot in almost every corner of the AI ecosystem, and the combination of everything it offers puts it in a prime position to be the biggest winner of AI,” said Luke O’Neill, CIO at CooksonPeirce Wealth Management, which holds stakes in both Alphabet and its primary AI rival, Nvidia.
The new funding round will be led by Thrive Capital, which also led Isomorphic Labs' initial financing, according to people familiar with the matter. Alphabet is also participating in the round, which has not yet closed. The investment comes as Alphabet raises its capital expenditure outlook for the year to as much as $190 billion to fund its AI ambitions, double what it spent in 2025.
This multi-billion dollar injection into a single AI drug discovery unit shows the immense value investors place on applying AI to complex scientific challenges. For Alphabet (GOOGL), it represents a push to move beyond its core advertising business and capture a piece of the high-margin drug development market, a domain historically led by Western pharmaceutical giants.
A New Engine for Innovation
Alphabet’s investment reflects a broader industry trend where the shrinking margins of contract manufacturing are pushing companies toward the high-risk, high-reward field of drug discovery. While India's pharmaceutical industry, valued at over $31 billion, is known as the "world's pharmacy" for its vast generic drug manufacturing, it has historically lagged in original drug discovery. AI is now seen as a critical tool to close that gap.
Isomorphic Labs aims to leverage the foundational AI models developed by DeepMind to create a new, more efficient paradigm for discovering novel medicines. The company’s goal is to reimagine the entire drug design process from the ground up with an AI-first approach, moving beyond simply assisting human chemists to building a fully automated platform for predicting how drugs will interact with the body.
The Broader AI Arms Race
The funding for Isomorphic is a key component of Alphabet's larger battle for AI supremacy against competitors like Nvidia. Once seen as an "AI afterthought," the Google parent has orchestrated a comeback, with investors cheering its multifaceted approach. The company's strategy involves not just developing its own powerful AI chips and models but also embedding AI into every facet of its business, from cloud services to ambitious scientific ventures.
To fuel this expansion, Alphabet is tapping global capital markets, recently planning its debut yen bond sale to widen its funding sources as AI competition intensifies. This massive capital allocation—with a planned $190 billion in capital expenditures—is aimed at building the infrastructure and talent needed to secure a long-term advantage in the AI era. For investors, the success of ventures like Isomorphic Labs could validate Alphabet's high-spend strategy and unlock new, non-advertising revenue streams that justify its position as one of the world's most valuable companies.
This article is for informational purposes only and does not constitute investment advice.
